News
UK researchers redesign needle used in IVF in a bid to boost success rates
The work is a culmination of five years of research into fertility
A team of UK researchers have redesigned the needle used in IVF procedures in a bid to boost success rates.
During IVF, eggs are taken from a woman’s ovaries and fertilised with sperm in a lab. Once fertilised, the egg becomes an embryo – which is then inserted into the womb to grow.
Gathering oocytes is invasive and expensive and, according to computer models, current techniques successfully collect only 60 per cent of available oocytes. The more oocytes that can be harvested, the more chance of a successful pregnancy.
The latest modelling research, led by Radu Cimpeanu, associate professor at Warwick Mathematics Institute at University of Warwick, has helped to improve the efficacy of the needles used in oocyte extraction.
The study, published in the Journal of Biomechanics, is a culmination of five years of research into fertility.
The researchers improved the efficacy of the needles through mathematical and computer models, which helped them study the complex flow of liquid through the needles used in IVF.
They showed that in traditional IVF methods, when the needle is inserted into follicles in the ovary to extract oocytes, the flow of fluids through the needle can damage the oocytes.
To address this, the team redesigned the needle to have specialised lateral channels, steering fluid flow inside the follicle to gently move the oocyte towards the hollow tip of the needle.
This, the researchers argued, would make it less likely for the oocytes to become stuck or damaged during extraction, improving collected numbers considerably at this early stage of the procedure.
“The study represents a fantastic interdisciplinary undertaking, with medical practitioners, engineers and mathematicians coming together to solve a problem from a completely new direction,” said Professor Cimpeanu.
“The study began in 2018, while I was at the University of Oxford, and quickly developed into an international collaboration.
“Seeing the models come to life as prototypes used in real-world studies has been an incredibly rewarding experience.”
Dr Ektoras Georgiou, subspecialist registrar in reproductive medicine and surgery at the University Hospital Southampton NHS Foundation Trust, said: “Modern IVF is a long and arduous process and its success rate is modest, at best.
“After leading a systematic review which demonstrated that the practice of follicular flushing does not improve oocyte yield or IVF outcomes, I found myself wondering how this now outdated process could be improved.
“It has been so exciting to be able to bring together a team of experts across different fields, who share in my passion to drive innovation in an evidence-based and scientific approach.”
The researchers, along with collaborators from the University of Nottingham and the Paragon Veterinary Group, tested the new type of needle in IVF procedures in cattle.
“We are currently laying the foundations for human trial studies and are in discussions with manufacturers to try to implement this new model at scale,” explained Cimpeanu.
“Alongside IVF, the research could have wide-reaching benefits, improving the use of needles in a range of medical treatments.”
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Fertility4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






